CAN2109
Advanced Solid Tumors
Phase 1Active
Key Facts
About Canwell Pharma
CanWell Pharma is a clinical-stage oncology biotech developing a pipeline of novel ADCs and SMDCs through its proprietary StarLinker and SMDC platforms. Key assets include CAN016, a dual-payload HER2 ADC with an FDA-cleared IND, and CAN1012, a TLR7 agonist with Orphan Drug Designation for soft tissue sarcoma. The company operates with a dual US-China strategy, advancing multiple programs from preclinical to early clinical development to address resistance and toxicity challenges in cancer therapy.
View full company profileTherapeutic Areas
Other Advanced Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NT219 | Purple Biotech | Phase 1/2 |
| INDP-101 | Indaptus Therapeutics | Phase 1 |
| NST-101 (estimated) | Novastage Pharmaceuticals | Phase 1/2 |
| Meta10-TILs | Leman Biotech | Phase 1 |
| PM14 | PharmaMar | Phase 1/2 |
| Ecubectedin (PM54) | PharmaMar | Phase 1 |
| M8891 | Merck KGaA | Phase 1/2 |
| P-002 | Panacea Biotec | Phase 1/2 |
| Undisclosed kinase inhibitor | Tyligand Bioscience | Phase 1 |
| TYK-001 | TYK Medicines | Phase 1/2 |
| PT-112 | SciClone Pharmaceuticals | Phase 1 |
| AP-202 | Advance Pharmaceutical | Phase 1/2 |